NCT01535924View on ClinicalTrials.gov

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 9, 2012

Primary Completion Date

February 20, 2019

Study Completion Date

February 20, 2019

Conditions
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Lymphocyte Predominant Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaRecurrent Adult Hodgkin Lymphoma
Interventions
DRUG

gemcitabine hydrochloride

Given IV

DRUG

bendamustine hydrochloride

Given IV

Trial Locations (2)

30322

Emory University, Atlanta

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors
lead

Beth Christian

OTHER

NCT01535924 - Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter